Data Resource Profile: Cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER) by Denaxas, SC et al.
DATA RESOURCE PROFILE
Data Resource Profile: Cardiovascular disease
research using linked bespoke studies and
electronic health records (CALIBER)
Spiros C Denaxas,1*y Julie George,1y Emily Herrett,2 Anoop D Shah,1 Dipak Kalra,3 Aroon D
Hingorani,1 Mika Kivimaki,1 Adam D Timmis,4 Liam Smeeth2 and Harry Hemingway1
1Department of Epidemiology and Public Health, Clinical Epidemiology, University College London, London, UK, 2Department of
Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK, 3Centre for Health
Informatics and Multi-professional Education, University College London, London, UK and 4National Institute for Health Research
Biomedical Research Unit, Barts Health, London, UK
*Corresponding author. Department of Epidemiology and Public Health, Clinical Epidemiology, University College London,
1-19 Torrington Place, London, WC1E 6BT, UK. E-mail: s.denaxas@ucl.ac.uk
yThese authors contributed equally to this work.
Accepted 4 October 2012
The goal of cardiovascular disease (CVD) research using linked
bespoke studies and electronic health records (CALIBER) is to pro-
vide evidence to inform health care and public health policy for
CVDs across different stages of translation, from discovery, through
evaluation in trials to implementation, where linkages to electronic
health records provide new scientific opportunities. The initial
approach of the CALIBER programme is characterized as follows:
(i) Linkages of multiple electronic heath record sources: examples
include linkages between the longitudinal primary care data from
the Clinical Practice Research Datalink, the national registry of
acute coronary syndromes (Myocardial Ischaemia National Audit
Project), hospitalization and procedure data from Hospital Episode
Statistics and cause-specific mortality and social deprivation data
from the Office of National Statistics. Current cohort analyses in-
volve a million people in initially healthy populations and disease
registries with 105 patients. (ii) Linkages of bespoke investigator-
led cohort studies (e.g. UK Biobank) to registry data (e.g.
Myocardial Ischaemia National Audit Project), providing new
means of ascertaining, validating and phenotyping disease. (iii) A
common data model in which routine electronic health record
data are made research ready, and sharable, by defining and
curating with meta-data 4300 variables (categorical, continuous,
event) on risk factors, CVDs and non-cardiovascular comorbidities.
(iv) Transparency: all CALIBER studies have an analytic protocol
registered in the public domain, and data are available (safe haven
model) for use subject to approvals. For more information, e-mail
s.denaxas@ucl.ac.uk
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Data resources basics
Using linked electronic health records for
translational research
The goal of cardiovascular disease (CVD) research
using linked bespoke studies and electronic health re-
cords (CALIBER) is to provide evidence across differ-
ent stages of translation, from discovery, through
evaluation to implementation where electronic
health records provide new scientific opportunities.
The expanding role of such record research with clin-
ical and public health impact has been extensively
reviewed.1–4 With healthy cohort sample sizes 106
and disease registries 105, such records offer a larger
scale and higher degree of phenotypic resolution5
than has been available in investigator led studies.
Opportunity
The UK is the only country in the world that has both
detailed electronic primary care records, and CVD and
procedure registries at a national scale, as well as
more standard sources such as cause-specific hospi-
talization and mortality records and census data (see
Table 1 and Table 2). Neither Sweden nor Denmark
has comparably rich national primary care data in
their respective linkage programmes. Scotland14,15
and Wales16,17 have established record-linkage pro-
grammes that have focused on diabetes and public
health research, respectively. Some centres have had
prominent research programmes in CVD with a focus
on prognosis and quality of care and drug safety re-
search in all phases of translational research in smal-
ler (105) populations such as the Institute of Clinical
and Evaluative Sciences in Canada18 and Yale, Duke,
Intermountain Heart Centre and the Mayo Clinic in
the USA.19 There have been few, if any, attempts to
establish an Electronic Health Record (EHR)-based
population-based cohort research platform in CVDs.
Who set CALIBER up and how was
it funded?
In 2012, the UK Government launched four new cen-
tres of EHR research in London, Manchester, Dundee
and Swansea. CALIBER is led from the London
centre, Centre for Health Service and Academic
Partnership in Translational Electronic health record
Research, Director Hemingway (CHAPTER) incorpor-
ating the National Institute for Cardiovascular
Outcomes Research (NICOR). CHAPTER is led from
University College London (UCL) and Partners,
which include UCL, the London School of Hygiene
and Tropical Medicine and Queen Mary University
of London. CALIBER investigators represent a collab-
oration between epidemiologists, clinicians, statisti-
cians, health informaticians and computer scientists
with initial funding from the Wellcome Trust and
the National Institute for Health Research. The first
tranche of raw-linked data was received in 2011.
Third party linkage was coordinated by the
Medicines and Healthcare products Regulatory
Agency.
Challenges
Researchers wishing to harness large-scale national
data sources or rich regional resources on imaging
and bioresources, on CVDs in the UK, face major
challenges:
(i) Lack of CVD–EHR research programmes span-
ning the entire translational cycle.20
Table 1 Availability of primary care data for research in different countries
Country
National or
regional Primary and ambulatory care data available for research linkages
UK National CPRD, access through Academic Health Sciences Networks. See Table 2
Sweden National Primary care is organized regionally; national initiatives in SwedeHeart6 and the National
Registry of Secondary Prevention (SEPHIA)
Denmark National Register of Medicinal Product Statistics7,8
Canada Regional Ontario, Institute for Clinical Evaluative Sciences9
Ontario Health Insurance Plan Physician claims database
USA National Medicare (for people aged 565 years)
National Million Veteran Programme
Regional Mayo Clinic10
Rochester Epidemiology Project, Olmsted County
Regional Kaiser Permanente California Research Program on Genes, Environment, and Health11
Regional Intermountain Healthcare12
South Korea National National health insurance claims database from the Health Insurance Review &
Assessment Service13
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(ii) Major national EHR sources (e.g. in NICOR)
remain unlinked among themselves or to inves-
tigator led studies.
(iii) Lack of understanding of the potential of differ-
ent record sources. Although the research
community is familiar with death and hospital-
ization records coded with the International
Classification of Disease, other EHR data sources,
e.g. primary care, have been much less used by
cardiovascular researchers. Poor adoption of
meta-data standards21 has led to little informa-
tion being available on how raw data might be
reliably converted into a useable form for re-
searchers, and data inconsistency problems,
both of which hinder replication of results and
data sharing.
(iv) Lack of transparency initiatives, which might
address well-recognized problems of selective
non-publication, selective reporting and signifi-
cance chasing biases.22
(v) Data quality has been inadequately tied to the
quality of the clinical care received.
CALIBER principles
CALIBER was established within CHAPTER, a centre
seeking to address these challenges. We set out below
our approach for:
 Linkage of multiple EHR data sources. (See Table 2
and Figure 1 for key features of five sources of data
currently linked in CALIBER.)
 Linkage with bespoke investigator led cohort
studies.
 Establishing a common data model with reprodu-
cible data variables and meta-data (see Figure 2
and Figure 3).
 Transparency—CALIBER studies are registered in
the public domain on clinicaltrials.gov, and their
analytic protocol is made available for download
(see Figure 4).
Table 2 Linked electronic health record sources in CALIBER: types of data, coding system used and data recording details
Sources Types of data Coding system
When and by whom data
is coded?
Primary care:
CPRD and
other
sources
Longitudinal primary care data
Diagnoses and symptoms irre-
spective of hospitalization,
drug prescriptions, vaccin-
ations, blood test results, risk
factors
Data recorded using the Read clin-
ical terminology system, version 3
contains 99 000 codes
Data recoded by the general
practitioner in real time
during the consultation
Hospital discharge letters
coded by a practice
administrator
Social depriv-
ation: ONS
Small area patient social depriv-
ation data
Index of Multiple Deprivation
(2007) and Townsend score
Derived from multiple
national administrative
data sets
Disease regis-
try: MINAP
National registry of Acute
Coronary Syndrome
admissions
Phenotype (ST Elevation
Myocardial Infarction, Non-ST
Elevation Myocardial
Infarction, Unstable Angina),
severity and treatment data
In all, 120 fields most with multiple
response categories, as defined by
the MINAP steering group
Recorded usually by audit
nurse, days or weeks after
admission, by abstracting
data from hospital records
Secondary
care: HES
National data warehouse of
hospitalizations recorded for
administrative purposes
Inpatient, outpatient, emergency,
critical care and maternity
admissionsa
Operations and surgical
procedures
Up to 20 primary and secondary
discharge diagnoses recorded
using ICD-10
Up to 24 codes using the Office of
Population, Censuses and Surveys
Classification of Surgical
Operations and Procedures and
used for operations
The 4th revision (OPCS-4) contains
10 000 codes
Recorded by non-clinical
trained coders based on the
discharge summary weeks
after discharge
Mortality:
ONS
National census of all deaths
Primary and underlying cause of
death
The primary, underlying and up to
14 secondary causes of death are
recorded using ICD-10
Doctor (general practitioner
or hospital) completes
death certificate with cause
of death. ICD codes added
by trained non-clinical
coders
aEmergency, critical care and maternity data not included in CALIBER for now.
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Figure 2 The CALIBER framework of transforming raw electronic health record data into usable research-ready data sets
Figure 1 Longitudinal nature of multiple linked data sources in CALIBER. ECG¼Electrocardiography, STEMI¼ST-seg-
ment elevation Myocardial Infarction, ACEI¼Angiotensin-converting-enzyme Inhibitor
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Data resource area and population
coverage
Figure 1 illustrates the longitudinal, population-based
nature of CALIBER data sets and how each source
captures a different aspect of the patient journey.
Current linkages in CALIBER involve the following:
the Clinical Practice Research Datalink (CPRD),23
the Myocardial Ischaemia National Audit Project
(MINAP),24 Hospital Episodes Statistics (HES)25 and
the Office for National Statistics (ONS) mortality26
and social deprivation data (Table 2).
CPRD is a longitudinal primary care data set and re-
cords data on symptoms, diagnosis prescriptions, inves-
tigations, referrals and vaccinations. Roughly 97% of
the population in the UK are registered with a general
practitioner (GP).27 Diagnostic data are coded using
Read codes,28 used in several countries in Europe and
which map to Systematic Nomenclature of Medicine –
Clinical Terms.29 The population of all CPRD practices
has been shown to be broadly representative of the
population of UK;23 the subset of practices consenting
to data-linkage shares the demographic profile of the
full CPRD data set. The CPRD has two key methods of
ensuring quality of the data made available to the re-
search community: the ‘acceptable research quality’
flag, a patient-level quality marker; and the Up To
Standard date, a practice-level quality marker.
MINAP is a national registry of patients admitted
to 230 hospitals in the UK with acute coronary syn-
drome (ACS) events. For each admission, MINAP
records patient demographic characteristics, limited
medical history, clinical features and investigations,
drug treatment (pre-, during and post-admission) and
final diagnosis, including differentiation into ST eleva-
tion MI, non-ST elevation MI and unstable angina.
HES is a national data set of all admissions to
National Health Service (NHS) hospitals in the UK.
Diagnoses are recorded using the International
Statistical Classification of Diseases and Health-
Related Problems, 10th revision (ICD-10)30 and proced-
ures using the Office of Population Censuses and
Surveys Classification of Interventions and Procedures
(OPCS) Version 4.31
The ONS provides data on cause-specific mortality
for all residents of the UK. Cause-specific mortality
data are extracted from death certificates and re-
corded using ICD-10. Small-area measures of social
deprivation are recorded using the Index of Multiple
Deprivation 200732 and Townsend scores.33
Linkage
A 10-digit numeric identifier, known as the NHS
number, uniquely identifies patients in the UK.
Number generation is centrally managed and not
Figure 3 Example of a CALIBER cohort showing initial presentation of specific cardiac endpoints (n¼ 32 390) with counts
and sources. Appendix A illustrates the approach to defining cardiovascular diseases using multiple record sources in
CALIBER
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Figure 4 Example of CALIBER research projects registered in the public domain
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derived from demographic information, enabling the
identification of patients throughout the NHS in an un-
ambiguous and unique way, making NHS numbers a
reliable and robust identifier for record linkage and data
sharing while preserving patient confidentiality.
Roughly 45% of 592 CPRD practices in the UK con-
sented to linkage of their registered patients. For these
participating practices, all patients registered at the
practice were included. Following the ‘separation prin-
ciple’,16 data were linked on NHS number, date of birth,
sex and post code by a Trusted Party (see Figure 2).
Measures
Converting raw data to research-ready data:
curated common data model
Figure 2 illustrates how CALIBER curates data from
multiple EHR sources, generating research-ready data
from raw data. CALIBER contains43 billion records
of raw data originating from multiple sources. The
recorded data are of variable quality, completeness
and specificity and unusable for research without
proper processing. We have created 4300 variables
on medical history, diagnosis, investigations, proced-
ures and prescriptions. Data from all of the source
data sets were used in the creation of these variables,
and each definition has been reviewed and agreed
by both clinical and non-clinical researchers in a
transparent and reproducible manner. Coding lists
containing Read codes, ICD-10 and OPCS-4 codes
were compiled for each variable in a reproducible
manner.34 Variables contain detailed response cate-
gories to provide individual researchers with the flexi-
bility to adjust the sensitivity and specificity of their
definitions according to their needs.
Variables are curated using established meta-data
standards35 and are versioned using a distributed
source control repository system (http://git-scm.com/),
which facilitates accurate tracking of changes over
time as it keeps all previous revisions of the variables
and records the changes between versions. CALIBER
researchers have access to the CALIBER online data
portal, which includes individual coding lists and
programming scripts used to extract both data and
clinical coding lists. For each variable, the data
portal entry contains the type, source data files,
valid range (if applicable), response categories, revi-
sion, implementation details and any other relevant
information such as references to published literature
or descriptive notes. This transparent and reproducible
manner of operation ensures that knowledge is fed
back into the platform and subsequently becomes
available for researchers to make further use of. For
example, if a potential researcher is working on an
exposure previously not defined within CALIBER,
the new variables they define would be incorporated
back into the data portal (following peer review) and
made available to other future researchers for use.
Metadata enable the automatic generation of the cen-
tralized data portal and documentation, keeping the
variable definition process synchronized with the re-
search data set creation and curation.
Figure 5 illustrates how CALIBER exploits multiple
EHR sources to create a robust data variable
(CALIBER hypertension). In total, 4700 clinical
terms were combined from three EHR sources to
create this composite variable, which defines a pa-
tient’s hypertensive status at a given time point. A
patient is considered hypertensive if they have been
diagnosed by a GP or within the past year have had at
least three measurements of raised systolic or diastolic
blood pressure or at least three records of raised blood
pressure or at least two prescriptions of blood pres-
sure lowering medication.
CALIBER data include all diagnosed co-existing
conditions irrespective of hospital attendance and
values of clinically collected circulating biomarkers
such as haemoglobin and prescriptions issued, includ-
ing medication type, timing and quantity. Detailed
mental health data on diagnosis and hospitalization
for numerous morbidities such as depression, anxiety,
bipolar disorder, schizophrenia and psychosis have been
included in the data portal (D Batty, personal
communication).
Frequency of data collection on
patients
Unlike traditional cohorts, in EHR cohorts follow-up is
continuous and initiated by capture within one or more
EHR source (Figure 1). In the example cohort (Figure
3), the median observation time from study entry date is
5.5 years, with an inter-quartile range (IQR) of 2.1–9.1.
Roughly 75.5% of people have at least two blood pres-
sure measurements, and the median number of meas-
urements in people with at least one measurement is 9
(IQR 4–20). The median number of BMI measurements
in people with at least one measurement is 3 (IQR 2–7),
and similarly the median number of total cholesterol
measurements are 3 (IQR 1–6). The mean annual con-
sultation rate at baseline is 7.9.
Biobanks and bespoke cohort linkages
Further linkages have also been established between
bespoke investigator led cohort studies and MINAP.
Such linkages provide traditional cohort studies with
higher-resolution ACS endpoints. Specifically, we
have coordinated the linkage between MINAP and
(i) the UK Collaborative Trial of Ovarian Cancer
Screening, a randomized trial of 200 000 post-meno-
pausal women aged 50–74 years;36 (ii) Whitehall II, a
cohort of 10 000 civil servants aged 35–55 years;37
and (iii) UK Biobank, a cohort of 500 000 middle-aged
adults with a range of physical measurements and
biological samples.38 Cross-referencing of acute myo-
cardial infarction in four sources is under way.
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Data resource use
One important use is to define cohorts using the
primary care as denominator population. An example
of such a CALIBER cohort (entry between years
2001–10) is shown in Figure 3. The sample consists of
901 629 adults aged530 years (39.54% men) registered
with a CPRD practice, which participates in the data
linkage and that have data of acceptable research qual-
ity, no prior atherosclerotic disease and complete base-
line data on age, sex, blood pressure, smoking, diabetes
status and lipid lowering medication information.
CALIBER resources are contributing new knowledge
at different stages in translational pathways, e.g.:
 Risk factors for initial presentation of CVDs:
CALIBER cohorts allow investigation of initial pres-
entation of a wide range of CVDs, which has hitherto
not been possible in smaller, less-well clinically phe-
notyped cohorts. For example smoking has hetero-
geneous associations with different CVD endpoints,
with no association with initial presentation with
ventricular arrhythmia or cardiac arrest, a modest
association with chronic stable angina and heart fail-
ure and strong associations with ACSs.39
 Prognosis: A new prognostic model for people with
stable coronary artery disease (CAD)40 has been de-
veloped and validated in a population of 100 000
patients with stable angina or who have become
stable after an ACS. We show that clinically collected
information, including biomarkers, provides signifi-
cant improvements in discrimination, risk re-
classification and clinical cost-effectiveness beyond
that achieved based on age, sex, CAD type and clin-
ical history alone.
 Quality of care and outcomes research: Two countries
in the world have MI registries, which include data
on consecutive patients in all hospitals. In compari-
sons of over half a million patients in Sweden and the
UK, there were important treatment differences, and
the 30-day mortality was lower in Sweden.41
 Pharmacoepidemiology: Although primary care data
have long been used for pharmacoepidemiology, new
CALIBER linkages with hospital event data from
MINAP and HES allowed CALIBER to contribute
new policy-relevant evidence on the potential
harms of clopidogrel discontinuation42 and the lack
of robust evidence of interaction between clopidogrel
use and proton pump inhibitors.43
Figure 5 Example of one CALIBER research variable, hypertension, created from multiple raw electronic health record sources.
The variable uses a combination of (i) repeat continuous blood pressure measurements; (ii) categorical data on measured blood
pressure (over 130 Read codes); (iii) hypertension diagnosis in primary care (over 180 Read codes); and (iv) prescription of blood
pressure lowering medications
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Future developments
The data resources accessible via CALIBER will grow in
CHAPTER in several respects including increasing the
scale of population coverage to design and implement
randomized trials within the primary care record and
within disease and procedure registries (NICOR), to in-
corporate bioresources allowing genomic approaches to
discovery and to use natural language processing of text
recorded in primary care. Planned extensions include
wider coverage of primary care data (current linked
CPRD data cover 8% and aims to include 25% by end
of 2012, maximizing the coverage by March 2016) and
linkage with wider disease and procedure registries in
NICOR. A key next step is to incorporate linkages with
integrated hospital records and integrate clinical re-
search with medical care on a large scale by unlocking
the full potential of data collected in such settings.
Existing platforms such as the National Institute for
Health Research Cardiovascular Biomedical Research
Unit, an integrated cardiovascular hospital records plat-
form spanning cardiac data, general trust-level systems,
radiology and genomics systems for 25 000 patients will
be expanded.
Strengths and weaknesses
CALIBER has potential strengths in the degree of clin-
ical, longitudinal phenotyping spanning ambulatory
and hospitalized care in large population samples. This
allows opportunities for a ‘higher resolution’ approach
to cardiovascular epidemiology in three respects. First,
most existing investigator led (bespoke) cardiovascular
cohorts study broad aggregates [CVD, coronary heart
disease (CHD)], or at most distinguish a narrow range
(typically two or three) of different diseases of interest.
As the causes, treatment and prognosis vary across a
range of disease phenotypes, CALIBER data sets have
the statistical size and clinical phenotyping allowing the
opportunity to ‘resolve’ these broad aggregates into dis-
tinct disease phenotypes in cerebral, peripheral and cor-
onary circulations. Figure 3 illustrates that cardiac
diseases include the following: chronic stable angina,
unstable angina, ST elevation myocardial infarction
(STEMI), non-ST elevation myocardial infarction
(NSTEMI), heart failure, ventricular arrhythmias and
cardiac arrest, sudden cardiac death and unheralded
coronary death. Use of four sources of data to define
endpoints is illustrated in Appendix A. Second, unlike
many investigator led cardiovascular cohorts, CALIBER
data sets have the temporal resolution to distinguish
whether a first event (e.g. heart attack or stroke) was
the first manifestation of CVD or whether it was pre-
ceded by any of a range of non-fatal (and often diag-
nosed in primary care) manifestations of CVD. Third,
most previous studies have been too small to under-
stand the interplay between different causal domains.
For example, even addressing the simple question
of gender differences in the smoking effect across
different specific cardiovascular endpoints necessitates
large samples. CALIBER cohorts have a sufficient
number of events and patients on which accurate esti-
mates of risk can be based.
The main weaknesses of any EHR research platform
relate to data quality.
Data quality in single sources
Data quality in single sources requires evaluation on
a case by case basis with a range of methods: cross-
referencing against chart review, against data col-
lected under research conditions and cross-sectional
and prospective tests of validity.
Missing data
Although some measurements, such as BMI, are rea-
sonably complete (82.6% of people with at least one
BMI measurement), others, such as total cholesterol,
are less complete (44.9% with at least one total chol-
esterol measurement). Developments in imputation of
missing data within such primary care longitudinal
cohorts are promising and might offer a partial solu-
tion to the problem.44 Variation in coding used across
practices and over time, as well the use of broader
diagnostic categories used (e.g. CHD Not Otherwise
Specified),45 may prove more difficult to resolve.
Conflicting data
Fatal MI may be recorded in up to four different
sources, which differ in their diagnostic granularity
and timing accuracy. Multiple records at similar
time points may reflect the same event or subsequent
events—e.g. an MI is recorded in CPRD, and, after
30 days in MINAP, could point to a single or recurrent
event (E Herrett, personal communication).
Linkage quality
There is empirical evidence46 that errors in data link-
age can lead to significantly different conclusions
about the associations of risk factors with outcomes.
The linkage method used for linking CALIBER con-
stituent data sets has been used before, and it has
been shown to yield reasonably high quality matches.
Data resource access
Raw data are available for use by researchers subject
to approval of the protocol by, and payment to, the
bodies governing access to the constituent data sets.
For CPRD, this involves scientific approval of the
protocol by the Independent Scientific Advisory
Committee and a signed licence outlining scope and
data confidentiality of use of CPRD data. For MINAP,
applications are made to the MINAP Academics
Group, and to the NHS Information Centre47 for
HES and ONS. Following such approvals, an applica-
tion to the CALIBER Scientific Advisory Committee
should be submitted.
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CALIBER researchers register their study and pub-
lish their protocol in the public domain before receiv-
ing data.48 Study registration and protocol publication
are of complementary nature; registration records pre-
sent short, standardized elements of the full protocol
in an accessible manner.
CALIBER welcomes collaborative research. Access
to data for external researchers (those who are not
affiliated with CALIBER investigators) is provided
within the CALIBER ‘safe haven’ environment,
which currently requires researchers to be physically
based in either UCL (Clinical Epidemiology Group) or
the London School of Hygiene and Tropical Medicine
(Smeeth). Given the diverse clinical origins, complex-
ity and size of the data sets, training with the
CALIBER team on data sources, coding, quality and
management is available.
The CALIBER data portal is available for consultation
online at http://www.caliberresearch.org/. Existing and
potential collaborators are encouraged to provide feed-
back on potential enhancements to the portal to facili-
tate the wider use of these data resources.
For more information, visit http://www.caliber
research.org/ or contact Dr Spiros Denaxas at
s.denaxas@ucl.ac.uk.
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KEY MESSAGES
CALIBER data resources provide a common framework for addressing questions of:
 Risk factors for initial presentation of a wide range of pathologically diverse CVDs: We have shown
that smoking has heterogeneous associations with different CVD endpoints.
 Prognosis: We have developed a new prognostic model for people with stable CAD, which makes use
of clinically collected information, including biomarkers.
 Quality of care and outcomes research: We observed significant treatment differences and lower 30-day
mortality in Sweden when comparing over half a million MI patients with the UK ACS registry.
 Pharmacoepidemiology: We have illustrated the potential harms of clopidogrel discontinuation and
the lack of robust evidence of interaction between clopidogrel use and proton pump inhibitors.
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